{"id":7913,"date":"2025-12-04T07:13:17","date_gmt":"2025-12-04T15:13:17","guid":{"rendered":"https:\/\/highfieldbio.com\/?p=7913"},"modified":"2025-12-04T07:41:13","modified_gmt":"2025-12-04T15:41:13","slug":"clinical-data-of-two-highfield-biopharmaceuticals-immuno-oncology-lipid-based-therapeutics-accepted-for-late-breaking-abstract-presentations-at-the-40th-anniversary-meeting-of-the-society-for-immuno-2","status":"publish","type":"post","link":"https:\/\/highfieldbio.com\/zh\/2025\/12\/04\/clinical-data-of-two-highfield-biopharmaceuticals-immuno-oncology-lipid-based-therapeutics-accepted-for-late-breaking-abstract-presentations-at-the-40th-anniversary-meeting-of-the-society-for-immuno-2\/","title":{"rendered":"HighField Biopharmaceuticals \u5728 2025 \u5e74\u764c\u75c7\u514d\u75ab\u6cbb\u7597\u5b66\u4f1a (SITC) \u4f1a\u8bae\u4e0a\u516c\u5e03\u4e86\u4e24\u79cd\u65b0\u578b\u8102\u8d28\u4f53\u80bf\u7624\u514d\u75ab\u7597\u6cd5\u7684\u4e34\u5e8a\u8bd5\u9a8c\u6837\u672c\u5206\u6790\u7ed3\u679c\u3002"},"content":{"rendered":"<div data-elementor-type=\"wp-post\" data-elementor-id=\"7913\" class=\"elementor elementor-7913\" data-elementor-post-type=\"post\">\n\t\t\t\t\t\t<section class=\"elementor-section elementor-top-section elementor-element elementor-element-7c3df96 elementor-section-boxed elementor-section-height-default elementor-section-height-default smart-sticky-default\" data-id=\"7c3df96\" data-element_type=\"section\">\r\n\t\t\t\t\t\t\t\t<div class=\"elementor-container elementor-column-gap-default\">\r\n\t\t\t\t\r\n\t\t\t\t\t\t\t\t<div class=\"elementor-column elementor-col-100 elementor-top-column elementor-element elementor-element-f09d554\" data-id=\"f09d554\" data-element_type=\"column\">\r\n\r\n\t\t\t\t\r\n\t\t\t\t<div class=\"elementor-widget-wrap elementor-element-populated\">\r\n\t\t\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t<div class=\"elementor-element elementor-element-33706a9 elementor-widget elementor-widget-spacer\" data-id=\"33706a9\" data-element_type=\"widget\" data-widget_type=\"spacer.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t<div class=\"elementor-spacer\">\n\t\t\t<div class=\"elementor-spacer-inner\"><\/div>\n\t\t<\/div>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-7f9ed22 elementor-widget elementor-widget-udesign_widget_heading\" data-id=\"7f9ed22\" data-element_type=\"widget\" data-widget_type=\"udesign_widget_heading.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t<div class=\"title-wrapper  title-cross title-center\"><p class=\"title elementor-heading-title\">2025\u5e7412\u67084\u65e5 | HighField Bio\u65b0\u95fb\u7a3f<\/p><\/div>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-b2ac3db elementor-widget elementor-widget-spacer\" data-id=\"b2ac3db\" data-element_type=\"widget\" data-widget_type=\"spacer.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t<div class=\"elementor-spacer\">\n\t\t\t<div class=\"elementor-spacer-inner\"><\/div>\n\t\t<\/div>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-ac618a2 elementor-widget elementor-widget-udesign_widget_heading\" data-id=\"ac618a2\" data-element_type=\"widget\" data-widget_type=\"udesign_widget_heading.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t<div class=\"title-wrapper  title-center\"><h2 class=\"title elementor-heading-title\">HighField Biopharmaceuticals \u5728 2025 \u5e74\u764c\u75c7\u514d\u75ab\u6cbb\u7597\u5b66\u4f1a (SITC) \u4f1a\u8bae\u4e0a\u516c\u5e03\u4e86\u4e24\u79cd\u65b0\u578b\u8102\u8d28\u4f53\u80bf\u7624\u514d\u75ab\u7597\u6cd5\u7684\u4e34\u5e8a\u8bd5\u9a8c\u6837\u672c\u5206\u6790\u7ed3\u679c\u3002<\/h2><\/div>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t\t<\/div>\r\n\t\t\t\t<\/div>\r\n\t\t\t\t\t\t\t\t<\/div>\r\n\t\t\t<\/section>\r\n\t\t\t\t\t<section class=\"elementor-section elementor-top-section elementor-element elementor-element-027104d alpha-section-stretched elementor-section-boxed elementor-section-height-default elementor-section-height-default smart-sticky-default\" data-id=\"027104d\" data-element_type=\"section\">\r\n\t\t\t\t\t\t\t\t<div class=\"elementor-container elementor-column-gap-default\">\r\n\t\t\t\t\r\n\t\t\t\t\t\t\t\t<div class=\"elementor-column elementor-col-100 elementor-top-column elementor-element elementor-element-a846582\" data-id=\"a846582\" data-element_type=\"column\">\r\n\r\n\t\t\t\t\r\n\t\t\t\t<div class=\"elementor-widget-wrap elementor-element-populated\">\r\n\t\t\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t<div class=\"elementor-element elementor-element-ed689c6 elementor-widget elementor-widget-text-editor\" data-id=\"ed689c6\" data-element_type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<ul><li style=\"text-align: center;\"><strong>HF50\uff08\u4e00\u79cd\u8102\u8d28\u4f53 T \u7ec6\u80de\u8854\u63a5\u5668\uff09\u7684\u9996\u6b21\u4eba\u4f53\u8bd5\u9a8c\u7ed3\u679c\u663e\u793a\uff0c\u5b83\u80fd\u5feb\u901f\u6fc0\u6d3b T \u8bb0\u5fc6\u5e72\u7ec6\u80de\u548c\u80bf\u7624\u9a7b\u7559\u7684 CD8 T \u7ec6\u80de\uff0c\u4ece\u800c\u4ea7\u751f\u6297\u80bf\u7624\u6d3b\u6027\uff0c\u4e14\u526f\u4f5c\u7528\u53ef\u63a7\u3002<\/strong><\/li><li style=\"text-align: center;\"><strong>HF1K16 I \u671f\u60a3\u8005\u6570\u636e\u5206\u6790\u7ed3\u679c\u8fd8\u663e\u793a\uff0cT \u5e7c\u7a1a\u5e72\u7ec6\u80de\u548c T \u8bb0\u5fc6\u5e72\u7ec6\u80de\u4e0e\u590d\u53d1\u548c\u96be\u6cbb\u6027\u80f6\u8d28\u7624\u60a3\u8005\u7684\u603b\u4f53\u751f\u5b58\u83b7\u76ca\u4e4b\u95f4\u5b58\u5728\u76f8\u5173\u6027\u3002<br \/><br \/><\/strong><\/li><\/ul>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-e59da4e elementor-widget-laptop__width-initial elementor-widget elementor-widget-text-editor\" data-id=\"e59da4e\" data-element_type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<p>\u4e2d\u56fd\u676d\u5dde\uff082025\u5e7412\u67084\u65e5\uff09\u2014\u2014\u4e13\u6ce8\u4e8e\u5229\u7528\u8102\u8d28\u7597\u6cd5\u6cbb\u7597\u764c\u75c7\u53ca\u5176\u4ed6\u75be\u75c5\u7684\u4e34\u5e8a\u9636\u6bb5\u516c\u53f8HighField Biopharmaceuticals\uff0c\u5728\u6700\u65b0\u7814\u7a76\u6458\u8981\u5c55\u793a\u73af\u8282\u4e2d\uff0c\u516c\u5e03\u4e86\u5176\u4e24\u6b3e\u72ec\u7279\u4e34\u5e8a\u9636\u6bb5\u4ea7\u54c1\u5728\u6cbb\u7597\u671f\u95f4\u91c7\u96c6\u7684\u4e34\u5e8a\u7814\u7a76\u60a3\u8005\u6837\u672c\u5206\u6790\u7ed3\u679c\uff0c\u63ed\u793a\u4e86\u5176\u7279\u5b9a\u7684\u514d\u75ab\u8c03\u8282\u673a\u5236\u3002 <a href=\"https:\/\/www.sitcancer.org\/2025\/home\">\u764c\u75c7\u514d\u75ab\u6cbb\u7597\u5b66\u4f1a (SITC) 40<sup>\u65e5<\/sup> \u5468\u5e74\u7eaa\u5ff5\u4f1a\u8bae<\/a> 2025\u5e7411\u6708\u3002<\/p><p>\u201cHighField Bio\u81f4\u529b\u4e8e\u5f00\u53d1\u57fa\u4e8e\u8102\u8d28\u7684\u4ea7\u54c1\uff0c\u91cd\u70b9\u5173\u6ce8\u6297\u764c\u514d\u75ab\u7684\u4e0d\u540c\u65b9\u9762\uff0c\u7528\u4e8e\u5b9e\u4f53\u7624\u6cbb\u7597\uff0c\u201d\u9996\u5e2d\u6267\u884c\u5b98\u517c\u79d1\u5b66\u521b\u59cb\u4eba\u5f90\u5b87\u7ea2\u535a\u58eb\u8868\u793a\uff0c\u201c\u8102\u8d28\u7eb3\u7c73\u7ed3\u6784\u5728\u5b9e\u4f53\u7624\u5fae\u73af\u5883\u4e2d\u5177\u6709\u72ec\u7279\u7684\u5206\u5e03\u7279\u6027\u3002\u6211\u4eec\u8ba4\u4e3a\u5b83\u4eec\u5728\u8c03\u8282\u80bf\u7624\u7ec4\u7ec7\u5185\u5404\u79cd\u514d\u75ab\u7ec6\u80de\u65b9\u9762\u53ef\u80fd\u5177\u6709\u5de8\u5927\u4f18\u52bf\uff0c\u4ece\u800c\u6062\u590d\u53d7\u635f\u7684\u6297\u80bf\u7624\u514d\u75ab\u529f\u80fd\u3002\u201d<\/p><p>HF50 \u6570\u636e\u4ee5\u6d77\u62a5\u5f62\u5f0f\u5448\u73b0\uff0c\u6807\u9898\u4e3a\u201c<a href=\"https:\/\/highfieldbio.com\/wp-content\/uploads\/2025\/12\/HIGHFIELD_SITC2025_HF50_P1314.pdf\"><strong>HF50\uff08\u4e00\u79cd\u65b0\u578b\u8102\u8d28\u4f53HER2xCD3 T\u7ec6\u80de\u8854\u63a5\u5668\uff0c\u5e26\u6709TLR\u6fc0\u52a8\u5242\u6709\u6548\u8f7d\u8377\uff09\u7684\u9996\u6b21\u4eba\u4f53\u8bc4\u4f30\u663e\u793a\u51fa\u826f\u597d\u7684\u8010\u53d7\u6027\u548c\u65e9\u671f\u4e34\u5e8a\u7597\u6548\u3002<\/strong><\/a>HF50\u662f\u4e00\u79cd\u8102\u8d28\u53cc\u5c42\u7cfb\u7edf\uff0c\u5176\u4e0a\u5206\u522b\u88c5\u6709\u9488\u5bf9T\u7ec6\u80de\u548c\u764c\u7ec6\u80de\u7684\u4e24\u79cd\u6297\u4f53\u3002\u8be5\u7cfb\u7edf\u8fd8\u5305\u62ec\u5c01\u88c5\u5728\u8102\u8d28\u4f53\u5185\u90e8\u7684\u514d\u75ab\u8c03\u8282\u5242\u3002<\/p><p>K16 \u6570\u636e\u4ee5\u6d77\u62a5\u5f62\u5f0f\u5448\u73b0\uff0c\u6807\u9898\u4e3a\u201c<a href=\"https:\/\/highfieldbio.com\/wp-content\/uploads\/2025\/12\/HIGHFIELD_SITC2025_HF1K16_P1350.pdf\" target=\"_blank\" rel=\"noopener\"><strong>\u5229\u7528 HF1K16 \u9776\u5411 MDSC \u53ef\u5ef6\u957f\u96be\u6cbb\u6027\u590d\u53d1\u6027\u80f6\u8d28\u7624\u60a3\u8005\u7684\u751f\u5b58\u671f\uff1bNCT05388487 \u7684\u6700\u65b0\u7814\u7a76\u8fdb\u5c55<\/strong><\/a>\u201cK16 \u662f\u4e00\u79cd\u542b\u6709\u5168\u53cd\u5f0f\u7ef4\u7532\u9178\u7684\u8102\u8d28\u4f53\uff0c\u53ef\u4fc3\u8fdb\u672a\u6210\u719f\u7684\u9ad3\u7cfb\u6765\u6e90\u6291\u5236\u7ec6\u80de (MDSC) \u5206\u5316\u4e3a\u6297\u539f\u5448\u9012\u7ec6\u80de (APC)\uff0c\u4ece\u800c\u589e\u5f3a\u5bf9\u764c\u7ec6\u80de\u7684\u7ec6\u80de\u6bd2\u6027\u514d\u75ab\u53cd\u5e94\u3002<\/p><p>\u5f90\u535a\u58eb\u8868\u793a\uff1a\u201c\u6839\u636e\u4e00\u671f\u4e34\u5e8a\u8bd5\u9a8c\u6570\u636e\uff0c\u4e24\u79cd\u7597\u6cd5\u5747\u8010\u53d7\u6027\u826f\u597d\uff0c\u5b89\u5168\u6027\u53ef\u63a7\u3002\u6b64\u5916\uff0c\u6211\u4eec\u5f88\u9ad8\u5174\u5730\u89c2\u5bdf\u5230K16\u5355\u836f\u6cbb\u7597\u7ec4\u60a3\u8005\u7684\u751f\u5b58\u83b7\u76ca\u663e\u8457\u3002\u76ee\u524d\uff0c2-3\u7ea7\u590d\u53d1\/\u96be\u6cbb\u6027\u80f6\u8d28\u7624\u60a3\u8005\u7684\u4e2d\u4f4d\u751f\u5b58\u671f\u4e3a26.5\u4e2a\u6708\uff0c4\u7ea7\u590d\u53d1\/\u96be\u6cbb\u6027\u80f6\u8d28\u7624\u60a3\u8005\u7684\u4e2d\u4f4d\u751f\u5b58\u671f\u4e3a17.7\u4e2a\u6708\u3002\u201d<\/p><p>\u5979\u8865\u5145\u9053\uff1a\u201cK16 \u548c HF50 \u7684\u8bbe\u8ba1\u76ee\u7684\u662f\u4e0e\u764c\u7ec6\u80de\u4fb5\u88ad\u514d\u75ab\u53cd\u5e94\u7ea7\u8054\u4e2d\u7684\u4e0d\u540c\u514d\u75ab\u7ec6\u80de\u76f8\u4e92\u4f5c\u7528\u3002\u5982\u4e0b\u56fe\u6240\u793a\uff0c\u764c\u75c7\u60a3\u8005\u6b63\u5e38\u7684\u80bf\u7624\u65b0\u6297\u539f\u5448\u9012\u548c\u6297\u764c\u514d\u75ab\u56de\u8def\u53d7\u5230\u5e72\u6270\u548c\u6291\u5236\u3002\u5982\u56fe\u4e2d\u7ea2\u8272\u7bad\u5934\u6240\u793a\uff0c\u521d\u59cb T \u7ec6\u80de\u548c T \u8bb0\u5fc6\u5e72\u7ec6\u80de\u4f1a\u8fc5\u901f\u53d8\u5f97\u4e0d\u654f\u611f\u5e76\u8017\u7aed\u3002\u201d<\/p><p>\u5f90\u535a\u58eb\u89e3\u91ca\u8bf4\uff1a\u201c\u4e0e\u514d\u75ab\u68c0\u67e5\u70b9\u6291\u5236\u5242\uff08\u56fe\u4e2d\u7eff\u8272\u7bad\u5934\u6240\u793a\uff09\u4e0d\u540c\uff0cK16 \u548c HF50 \u4ea7\u751f\u7684\u6cbb\u7597\u53cd\u5e94\u4e0d\u540c\u3002K16 \u4f5c\u7528\u4e8e\u672a\u6210\u719f\u7684\u9ad3\u6e90\u6027\u6291\u5236\u7ec6\u80de (MDSC)\uff0c\u5c06\u5176\u8f6c\u5316\u4e3a\u6297\u539f\u5448\u9012\u7ec6\u80de (APC)\uff0c\u4ece\u800c\u6062\u590d\u80bf\u7624\u8bc6\u522b\u548c\u7ec6\u80de\u6bd2\u6027 T \u7ec6\u80de\u7684\u6d3b\u6027\u3002HF50 \u7684\u4f5c\u7528\u8303\u56f4\u66f4\u5e7f\u3002\u6211\u4eec\u89c2\u5bdf\u5230\uff0c\u60a3\u8005\u63a5\u53d7 HF50 \u6cbb\u7597\u540e\uff0c\u591a\u79cd T \u7ec6\u80de\u88ab\u6fc0\u6d3b\uff0c\u5305\u62ec\u5e7c\u7a1a T \u7ec6\u80de\u548c\u8bb0\u5fc6\u5e72\u7ec6\u80de\u3002\u201d<\/p><p>\u5f90\u535a\u58eb\u8868\u793a\uff0c\u57fa\u4e8e\u8fd9\u4e9b\u53d1\u73b0\uff0c\u201c\u6211\u4eec\u5c06\u7ee7\u7eed\u52aa\u529b\u63a8\u8fdb HF50 \u548c K16 \u7684\u7814\u53d1\uff0c\u4ee5\u663e\u8457\u6539\u5584\u66f4\u591a\u764c\u75c7\u60a3\u8005\u7684\u6cbb\u7597\u6548\u679c\uff0c\u5e76\u51cf\u5c11\u526f\u4f5c\u7528\u3002\u201d<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-4ec3fb1 elementor-widget elementor-widget-image\" data-id=\"4ec3fb1\" data-element_type=\"widget\" data-widget_type=\"image.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<img fetchpriority=\"high\" decoding=\"async\" width=\"768\" height=\"490\" src=\"https:\/\/highfieldbio.com\/wp-content\/uploads\/2025\/12\/HIGHFIELD_SITCPosterPRImage_hires-768x490.jpg\" class=\"attachment-medium_large size-medium_large wp-image-7925\" alt=\"\" \/>\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-22c3ac2 elementor-widget-laptop__width-initial elementor-widget elementor-widget-text-editor\" data-id=\"22c3ac2\" data-element_type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<p><strong>\u5173\u4e8e HighField \u751f\u7269\u5236\u836f<\/strong><\/p><p>Highfield \u662f\u4e00\u5bb6\u4e34\u5e8a\u9636\u6bb5\u516c\u53f8\uff0c\u4e13\u6ce8\u4e8e\u9488\u5bf9\u514d\u75ab\u80bf\u7624\u5b66\u548c\u57fa\u56e0\u6cbb\u7597\u7684\u8102\u8d28\u4f53\u7ed3\u6784\u7684\u65b0\u5e94\u7528\u3002HighField \u5728\u4e34\u5e8a\u8bd5\u9a8c\u4e2d\u7684\u4e3b\u5bfc\u4ea7\u54c1\u662f K1\uff0c\u6e90\u81ea\u5176 ADCplex<sup>\u5546\u6807<\/sup> \u5e73\u53f0\uff0c\u968f\u540e\u662f HF50\uff0c\u6e90\u81ea\u5176 TCEplex<sup>\u5546\u6807 <\/sup>\u5e73\u53f0\u3002\u8be5\u516c\u53f8\u7684\u4ea7\u54c1\u7ebf\u8fd8\u5305\u62ec K16\uff0c\u4e00\u79cd\u836f\u7269\u5305\u88f9\u7684\u514d\u75ab\u8c03\u8282\u8102\u8d28\u4f53\uff0c\u9776\u5411\u9aa8\u9ad3\u6765\u6e90\u7684\u6291\u5236\u7ec6\u80de\uff0c\u7528\u4e8e\u96be\u6cbb\u6027\u764c\u75c7\u7684\u4e34\u5e8a\u8bd5\u9a8c\uff1b\u4ee5\u53ca\u6e90\u81ea\u5176 tLNPplex\u2122 \u5e73\u53f0\u7684 HFG1\uff0c\u7528\u4e8e GLP-1R \u6fc0\u52a8\u5242\u7684 mRNA \u8868\u8fbe\uff0c\u7528\u4e8e\u51cf\u80a5\u548c\u6cbb\u7597\u7cd6\u5c3f\u75c5\u3002\u6709\u5173\u66f4\u591a\u4fe1\u606f\uff0c\u8bf7\u8bbf\u95ee <a href=\"https:\/\/highfieldbio.com\/zh\">highfieldbio.com<\/a>.<\/p><p>\u00a0<\/p><p>\u5a92\u4f53\u8054\u7cfb\u65b9\u5f0f\uff1a<br \/>\u4e39\u00b7\u57c3\u62c9\u7c73\u5b89<br \/>Opus \u751f\u7269\u6280\u672f\u901a\u8baf<br \/><a href=\"mailto:danieleramian@comcast.net\">danieleramian@comcast.net<\/a>425-306-8716<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t\t<\/div>\r\n\t\t\t\t<\/div>\r\n\t\t\t\t\t\t\t\t<\/div>\r\n\t\t\t<\/section>\r\n\t\t\t\t\t<\/div>","protected":false},"excerpt":{"rendered":"<p>HighField Biopharmaceuticals \u5728 2025 \u5e74\u764c\u75c7\u514d\u75ab\u6cbb\u7597\u5b66\u4f1a (SITC) \u4f1a\u8bae\u4e0a\u516c\u5e03\u4e86\u4e24\u79cd\u65b0\u578b\u8102\u8d28\u4f53\u80bf\u7624\u514d\u75ab\u7597\u6cd5\u7684\u4e34\u5e8a\u8bd5\u9a8c\u6837\u672c\u5206\u6790\u7ed3\u679c\u3002HF50 \u662f\u4e00\u79cd\u8102\u8d28\u4f53 T \u7ec6\u80de\u8854\u63a5\u5668\uff0c\u5176\u9996\u6b21\u4eba\u4f53\u8bd5\u9a8c\u7ed3\u679c\u663e\u793a\uff0cHF50 \u80fd\u591f\u5feb\u901f\u6fc0\u6d3b T \u8bb0\u5fc6\u5e72\u7ec6\u80de\u548c\u80bf\u7624\u9a7b\u7559 CD8 T \u7ec6\u80de\uff0c\u4ece\u800c\u53d1\u6325\u6297\u80bf\u7624\u4f5c\u7528 [\u2026]<\/p>","protected":false},"author":1,"featured_media":7606,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_exactmetrics_skip_tracking":false,"_exactmetrics_sitenote_active":false,"_exactmetrics_sitenote_note":"","_exactmetrics_sitenote_category":0,"footnotes":"","_links_to":"","_links_to_target":""},"categories":[22],"tags":[],"class_list":["post-7913","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-press-release"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v26.0 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>HighField Biopharmaceuticals Presents Clinical Trial Sample Analysis of 2 Novel Lipid-Based Immuno-Oncology Therapeutics at the Society for Immunotherapy of Cancer (SITC) 2025 Meeting - HighField Biopharmaceuticals<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/highfieldbio.com\/zh\/2025\/12\/04\/clinical-data-of-two-highfield-biopharmaceuticals-immuno-oncology-lipid-based-therapeutics-accepted-for-late-breaking-abstract-presentations-at-the-40th-anniversary-meeting-of-the-society-for-immuno-2\/\" \/>\n<meta property=\"og:locale\" content=\"zh_CN\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"HighField Biopharmaceuticals Presents Clinical Trial Sample Analysis of 2 Novel Lipid-Based Immuno-Oncology Therapeutics at the Society for Immunotherapy of Cancer (SITC) 2025 Meeting - HighField Biopharmaceuticals\" \/>\n<meta property=\"og:description\" content=\"HighField Biopharmaceuticals Presents Clinical Trial Sample Analysis of 2 Novel Lipid-Based Immuno-Oncology Therapeutics at the Society for Immunotherapy of Cancer (SITC) 2025 Meeting Findings from the first-in-human trial of HF50, a liposomal T cell engager, revealed a fast activation scheme of both T memory stem cells and tumor residing CD8 T cells leading to anti-tumor [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/highfieldbio.com\/zh\/2025\/12\/04\/clinical-data-of-two-highfield-biopharmaceuticals-immuno-oncology-lipid-based-therapeutics-accepted-for-late-breaking-abstract-presentations-at-the-40th-anniversary-meeting-of-the-society-for-immuno-2\/\" \/>\n<meta property=\"og:site_name\" content=\"HighField Biopharmaceuticals\" \/>\n<meta property=\"article:published_time\" content=\"2025-12-04T15:13:17+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-12-04T15:41:13+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/highfieldbio.com\/wp-content\/uploads\/2025\/04\/HIGHIELD_LinkedIn_INDfiles.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1200\" \/>\n\t<meta property=\"og:image:height\" content=\"800\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"PJWCreative\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/highfieldbio.com\/2025\/12\/04\/clinical-data-of-two-highfield-biopharmaceuticals-immuno-oncology-lipid-based-therapeutics-accepted-for-late-breaking-abstract-presentations-at-the-40th-anniversary-meeting-of-the-society-for-immuno-2\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/highfieldbio.com\/2025\/12\/04\/clinical-data-of-two-highfield-biopharmaceuticals-immuno-oncology-lipid-based-therapeutics-accepted-for-late-breaking-abstract-presentations-at-the-40th-anniversary-meeting-of-the-society-for-immuno-2\/\"},\"author\":{\"name\":\"PJWCreative\",\"@id\":\"https:\/\/highfieldbio.com\/#\/schema\/person\/7ec00570bf3fa5a022cd1b08bda3b0f0\"},\"headline\":\"HighField Biopharmaceuticals Presents Clinical Trial Sample Analysis of 2 Novel Lipid-Based Immuno-Oncology Therapeutics at the Society for Immunotherapy of Cancer (SITC) 2025 Meeting\",\"datePublished\":\"2025-12-04T15:13:17+00:00\",\"dateModified\":\"2025-12-04T15:41:13+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/highfieldbio.com\/2025\/12\/04\/clinical-data-of-two-highfield-biopharmaceuticals-immuno-oncology-lipid-based-therapeutics-accepted-for-late-breaking-abstract-presentations-at-the-40th-anniversary-meeting-of-the-society-for-immuno-2\/\"},\"wordCount\":674,\"publisher\":{\"@id\":\"https:\/\/highfieldbio.com\/#organization\"},\"image\":{\"@id\":\"https:\/\/highfieldbio.com\/2025\/12\/04\/clinical-data-of-two-highfield-biopharmaceuticals-immuno-oncology-lipid-based-therapeutics-accepted-for-late-breaking-abstract-presentations-at-the-40th-anniversary-meeting-of-the-society-for-immuno-2\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/highfieldbio.com\/wp-content\/uploads\/2025\/04\/HIGHIELD_LinkedIn_INDfiles.jpg\",\"articleSection\":[\"Press Release\"],\"inLanguage\":\"zh-Hans\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/highfieldbio.com\/2025\/12\/04\/clinical-data-of-two-highfield-biopharmaceuticals-immuno-oncology-lipid-based-therapeutics-accepted-for-late-breaking-abstract-presentations-at-the-40th-anniversary-meeting-of-the-society-for-immuno-2\/\",\"url\":\"https:\/\/highfieldbio.com\/2025\/12\/04\/clinical-data-of-two-highfield-biopharmaceuticals-immuno-oncology-lipid-based-therapeutics-accepted-for-late-breaking-abstract-presentations-at-the-40th-anniversary-meeting-of-the-society-for-immuno-2\/\",\"name\":\"HighField Biopharmaceuticals Presents Clinical Trial Sample Analysis of 2 Novel Lipid-Based Immuno-Oncology Therapeutics at the Society for Immunotherapy of Cancer (SITC) 2025 Meeting - HighField Biopharmaceuticals\",\"isPartOf\":{\"@id\":\"https:\/\/highfieldbio.com\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/highfieldbio.com\/2025\/12\/04\/clinical-data-of-two-highfield-biopharmaceuticals-immuno-oncology-lipid-based-therapeutics-accepted-for-late-breaking-abstract-presentations-at-the-40th-anniversary-meeting-of-the-society-for-immuno-2\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/highfieldbio.com\/2025\/12\/04\/clinical-data-of-two-highfield-biopharmaceuticals-immuno-oncology-lipid-based-therapeutics-accepted-for-late-breaking-abstract-presentations-at-the-40th-anniversary-meeting-of-the-society-for-immuno-2\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/highfieldbio.com\/wp-content\/uploads\/2025\/04\/HIGHIELD_LinkedIn_INDfiles.jpg\",\"datePublished\":\"2025-12-04T15:13:17+00:00\",\"dateModified\":\"2025-12-04T15:41:13+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/highfieldbio.com\/2025\/12\/04\/clinical-data-of-two-highfield-biopharmaceuticals-immuno-oncology-lipid-based-therapeutics-accepted-for-late-breaking-abstract-presentations-at-the-40th-anniversary-meeting-of-the-society-for-immuno-2\/#breadcrumb\"},\"inLanguage\":\"zh-Hans\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/highfieldbio.com\/2025\/12\/04\/clinical-data-of-two-highfield-biopharmaceuticals-immuno-oncology-lipid-based-therapeutics-accepted-for-late-breaking-abstract-presentations-at-the-40th-anniversary-meeting-of-the-society-for-immuno-2\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"zh-Hans\",\"@id\":\"https:\/\/highfieldbio.com\/2025\/12\/04\/clinical-data-of-two-highfield-biopharmaceuticals-immuno-oncology-lipid-based-therapeutics-accepted-for-late-breaking-abstract-presentations-at-the-40th-anniversary-meeting-of-the-society-for-immuno-2\/#primaryimage\",\"url\":\"https:\/\/highfieldbio.com\/wp-content\/uploads\/2025\/04\/HIGHIELD_LinkedIn_INDfiles.jpg\",\"contentUrl\":\"https:\/\/highfieldbio.com\/wp-content\/uploads\/2025\/04\/HIGHIELD_LinkedIn_INDfiles.jpg\",\"width\":1200,\"height\":800},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/highfieldbio.com\/2025\/12\/04\/clinical-data-of-two-highfield-biopharmaceuticals-immuno-oncology-lipid-based-therapeutics-accepted-for-late-breaking-abstract-presentations-at-the-40th-anniversary-meeting-of-the-society-for-immuno-2\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/highfieldbio.com\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"HighField Biopharmaceuticals Presents Clinical Trial Sample Analysis of 2 Novel Lipid-Based Immuno-Oncology Therapeutics at the Society for Immunotherapy of Cancer (SITC) 2025 Meeting\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/highfieldbio.com\/#website\",\"url\":\"https:\/\/highfieldbio.com\/\",\"name\":\"HighField Bio\",\"description\":\"Lipid-based Therapeutics Targeting the Tumor Microenvironment\",\"publisher\":{\"@id\":\"https:\/\/highfieldbio.com\/#organization\"},\"alternateName\":\"HighField Biopharmaceuticals\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/highfieldbio.com\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"zh-Hans\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/highfieldbio.com\/#organization\",\"name\":\"HighField Biopharmaceuticals, Inc.\",\"alternateName\":\"HighField Bio\",\"url\":\"https:\/\/highfieldbio.com\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"zh-Hans\",\"@id\":\"https:\/\/highfieldbio.com\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/highfieldbio.com\/wp-content\/uploads\/2021\/07\/HIGHfield_logo_horizontal_FINAL_trans.png\",\"contentUrl\":\"https:\/\/highfieldbio.com\/wp-content\/uploads\/2021\/07\/HIGHfield_logo_horizontal_FINAL_trans.png\",\"width\":1500,\"height\":494,\"caption\":\"HighField Biopharmaceuticals, Inc.\"},\"image\":{\"@id\":\"https:\/\/highfieldbio.com\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.linkedin.com\/company\/highfield-biopharma\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/highfieldbio.com\/#\/schema\/person\/7ec00570bf3fa5a022cd1b08bda3b0f0\",\"name\":\"PJWCreative\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"zh-Hans\",\"@id\":\"https:\/\/highfieldbio.com\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/7558191085f3c167c2c5972a9ba86696e53fc4dec7eeb7b3e0cc15866c48b55f?s=80&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/7558191085f3c167c2c5972a9ba86696e53fc4dec7eeb7b3e0cc15866c48b55f?s=80&d=mm&r=g\",\"caption\":\"PJWCreative\"},\"sameAs\":[\"https:\/\/highfieldbio.com\"],\"url\":\"https:\/\/highfieldbio.com\/zh\/author\/pjwcreative\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"HighField Biopharmaceuticals \u5728 2025 \u5e74\u764c\u75c7\u514d\u75ab\u6cbb\u7597\u5b66\u4f1a (SITC) \u4f1a\u8bae\u4e0a\u5c55\u793a\u4e86\u4e24\u79cd\u65b0\u578b\u8102\u8d28\u4f53\u80bf\u7624\u514d\u75ab\u7597\u6cd5\u7684\u4e34\u5e8a\u8bd5\u9a8c\u6837\u672c\u5206\u6790\u7ed3\u679c - HighField Biopharmaceuticals","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/highfieldbio.com\/zh\/2025\/12\/04\/clinical-data-of-two-highfield-biopharmaceuticals-immuno-oncology-lipid-based-therapeutics-accepted-for-late-breaking-abstract-presentations-at-the-40th-anniversary-meeting-of-the-society-for-immuno-2\/","og_locale":"zh_CN","og_type":"article","og_title":"HighField Biopharmaceuticals Presents Clinical Trial Sample Analysis of 2 Novel Lipid-Based Immuno-Oncology Therapeutics at the Society for Immunotherapy of Cancer (SITC) 2025 Meeting - HighField Biopharmaceuticals","og_description":"HighField Biopharmaceuticals Presents Clinical Trial Sample Analysis of 2 Novel Lipid-Based Immuno-Oncology Therapeutics at the Society for Immunotherapy of Cancer (SITC) 2025 Meeting Findings from the first-in-human trial of HF50, a liposomal T cell engager, revealed a fast activation scheme of both T memory stem cells and tumor residing CD8 T cells leading to anti-tumor [&hellip;]","og_url":"https:\/\/highfieldbio.com\/zh\/2025\/12\/04\/clinical-data-of-two-highfield-biopharmaceuticals-immuno-oncology-lipid-based-therapeutics-accepted-for-late-breaking-abstract-presentations-at-the-40th-anniversary-meeting-of-the-society-for-immuno-2\/","og_site_name":"HighField Biopharmaceuticals","article_published_time":"2025-12-04T15:13:17+00:00","article_modified_time":"2025-12-04T15:41:13+00:00","og_image":[{"width":1200,"height":800,"url":"https:\/\/highfieldbio.com\/wp-content\/uploads\/2025\/04\/HIGHIELD_LinkedIn_INDfiles.jpg","type":"image\/jpeg"}],"author":"PJWCreative","twitter_card":"summary_large_image","schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/highfieldbio.com\/2025\/12\/04\/clinical-data-of-two-highfield-biopharmaceuticals-immuno-oncology-lipid-based-therapeutics-accepted-for-late-breaking-abstract-presentations-at-the-40th-anniversary-meeting-of-the-society-for-immuno-2\/#article","isPartOf":{"@id":"https:\/\/highfieldbio.com\/2025\/12\/04\/clinical-data-of-two-highfield-biopharmaceuticals-immuno-oncology-lipid-based-therapeutics-accepted-for-late-breaking-abstract-presentations-at-the-40th-anniversary-meeting-of-the-society-for-immuno-2\/"},"author":{"name":"PJWCreative","@id":"https:\/\/highfieldbio.com\/#\/schema\/person\/7ec00570bf3fa5a022cd1b08bda3b0f0"},"headline":"HighField Biopharmaceuticals Presents Clinical Trial Sample Analysis of 2 Novel Lipid-Based Immuno-Oncology Therapeutics at the Society for Immunotherapy of Cancer (SITC) 2025 Meeting","datePublished":"2025-12-04T15:13:17+00:00","dateModified":"2025-12-04T15:41:13+00:00","mainEntityOfPage":{"@id":"https:\/\/highfieldbio.com\/2025\/12\/04\/clinical-data-of-two-highfield-biopharmaceuticals-immuno-oncology-lipid-based-therapeutics-accepted-for-late-breaking-abstract-presentations-at-the-40th-anniversary-meeting-of-the-society-for-immuno-2\/"},"wordCount":674,"publisher":{"@id":"https:\/\/highfieldbio.com\/#organization"},"image":{"@id":"https:\/\/highfieldbio.com\/2025\/12\/04\/clinical-data-of-two-highfield-biopharmaceuticals-immuno-oncology-lipid-based-therapeutics-accepted-for-late-breaking-abstract-presentations-at-the-40th-anniversary-meeting-of-the-society-for-immuno-2\/#primaryimage"},"thumbnailUrl":"https:\/\/highfieldbio.com\/wp-content\/uploads\/2025\/04\/HIGHIELD_LinkedIn_INDfiles.jpg","articleSection":["Press Release"],"inLanguage":"zh-Hans"},{"@type":"WebPage","@id":"https:\/\/highfieldbio.com\/2025\/12\/04\/clinical-data-of-two-highfield-biopharmaceuticals-immuno-oncology-lipid-based-therapeutics-accepted-for-late-breaking-abstract-presentations-at-the-40th-anniversary-meeting-of-the-society-for-immuno-2\/","url":"https:\/\/highfieldbio.com\/2025\/12\/04\/clinical-data-of-two-highfield-biopharmaceuticals-immuno-oncology-lipid-based-therapeutics-accepted-for-late-breaking-abstract-presentations-at-the-40th-anniversary-meeting-of-the-society-for-immuno-2\/","name":"HighField Biopharmaceuticals \u5728 2025 \u5e74\u764c\u75c7\u514d\u75ab\u6cbb\u7597\u5b66\u4f1a (SITC) \u4f1a\u8bae\u4e0a\u5c55\u793a\u4e86\u4e24\u79cd\u65b0\u578b\u8102\u8d28\u4f53\u80bf\u7624\u514d\u75ab\u7597\u6cd5\u7684\u4e34\u5e8a\u8bd5\u9a8c\u6837\u672c\u5206\u6790\u7ed3\u679c - HighField Biopharmaceuticals","isPartOf":{"@id":"https:\/\/highfieldbio.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/highfieldbio.com\/2025\/12\/04\/clinical-data-of-two-highfield-biopharmaceuticals-immuno-oncology-lipid-based-therapeutics-accepted-for-late-breaking-abstract-presentations-at-the-40th-anniversary-meeting-of-the-society-for-immuno-2\/#primaryimage"},"image":{"@id":"https:\/\/highfieldbio.com\/2025\/12\/04\/clinical-data-of-two-highfield-biopharmaceuticals-immuno-oncology-lipid-based-therapeutics-accepted-for-late-breaking-abstract-presentations-at-the-40th-anniversary-meeting-of-the-society-for-immuno-2\/#primaryimage"},"thumbnailUrl":"https:\/\/highfieldbio.com\/wp-content\/uploads\/2025\/04\/HIGHIELD_LinkedIn_INDfiles.jpg","datePublished":"2025-12-04T15:13:17+00:00","dateModified":"2025-12-04T15:41:13+00:00","breadcrumb":{"@id":"https:\/\/highfieldbio.com\/2025\/12\/04\/clinical-data-of-two-highfield-biopharmaceuticals-immuno-oncology-lipid-based-therapeutics-accepted-for-late-breaking-abstract-presentations-at-the-40th-anniversary-meeting-of-the-society-for-immuno-2\/#breadcrumb"},"inLanguage":"zh-Hans","potentialAction":[{"@type":"ReadAction","target":["https:\/\/highfieldbio.com\/2025\/12\/04\/clinical-data-of-two-highfield-biopharmaceuticals-immuno-oncology-lipid-based-therapeutics-accepted-for-late-breaking-abstract-presentations-at-the-40th-anniversary-meeting-of-the-society-for-immuno-2\/"]}]},{"@type":"ImageObject","inLanguage":"zh-Hans","@id":"https:\/\/highfieldbio.com\/2025\/12\/04\/clinical-data-of-two-highfield-biopharmaceuticals-immuno-oncology-lipid-based-therapeutics-accepted-for-late-breaking-abstract-presentations-at-the-40th-anniversary-meeting-of-the-society-for-immuno-2\/#primaryimage","url":"https:\/\/highfieldbio.com\/wp-content\/uploads\/2025\/04\/HIGHIELD_LinkedIn_INDfiles.jpg","contentUrl":"https:\/\/highfieldbio.com\/wp-content\/uploads\/2025\/04\/HIGHIELD_LinkedIn_INDfiles.jpg","width":1200,"height":800},{"@type":"BreadcrumbList","@id":"https:\/\/highfieldbio.com\/2025\/12\/04\/clinical-data-of-two-highfield-biopharmaceuticals-immuno-oncology-lipid-based-therapeutics-accepted-for-late-breaking-abstract-presentations-at-the-40th-anniversary-meeting-of-the-society-for-immuno-2\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/highfieldbio.com\/"},{"@type":"ListItem","position":2,"name":"HighField Biopharmaceuticals Presents Clinical Trial Sample Analysis of 2 Novel Lipid-Based Immuno-Oncology Therapeutics at the Society for Immunotherapy of Cancer (SITC) 2025 Meeting"}]},{"@type":"WebSite","@id":"https:\/\/highfieldbio.com\/#website","url":"https:\/\/highfieldbio.com\/","name":"\u9ad8\u7530\u751f\u7269","description":"\u9488\u5bf9\u80bf\u7624\u5fae\u73af\u5883\u7684\u8102\u8d28\u7597\u6cd5","publisher":{"@id":"https:\/\/highfieldbio.com\/#organization"},"alternateName":"HighField Biopharmaceuticals","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/highfieldbio.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"zh-Hans"},{"@type":"Organization","@id":"https:\/\/highfieldbio.com\/#organization","name":"\u6d77\u83f2\u5c14\u5fb7\u751f\u7269\u5236\u836f\u6709\u9650\u516c\u53f8","alternateName":"HighField Bio","url":"https:\/\/highfieldbio.com\/","logo":{"@type":"ImageObject","inLanguage":"zh-Hans","@id":"https:\/\/highfieldbio.com\/#\/schema\/logo\/image\/","url":"https:\/\/highfieldbio.com\/wp-content\/uploads\/2021\/07\/HIGHfield_logo_horizontal_FINAL_trans.png","contentUrl":"https:\/\/highfieldbio.com\/wp-content\/uploads\/2021\/07\/HIGHfield_logo_horizontal_FINAL_trans.png","width":1500,"height":494,"caption":"HighField Biopharmaceuticals, Inc."},"image":{"@id":"https:\/\/highfieldbio.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.linkedin.com\/company\/highfield-biopharma"]},{"@type":"Person","@id":"https:\/\/highfieldbio.com\/#\/schema\/person\/7ec00570bf3fa5a022cd1b08bda3b0f0","name":"PJW\u521b\u610f","image":{"@type":"ImageObject","inLanguage":"zh-Hans","@id":"https:\/\/highfieldbio.com\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/7558191085f3c167c2c5972a9ba86696e53fc4dec7eeb7b3e0cc15866c48b55f?s=80&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/7558191085f3c167c2c5972a9ba86696e53fc4dec7eeb7b3e0cc15866c48b55f?s=80&d=mm&r=g","caption":"PJWCreative"},"sameAs":["https:\/\/highfieldbio.com"],"url":"https:\/\/highfieldbio.com\/zh\/author\/pjwcreative\/"}]}},"_links":{"self":[{"href":"https:\/\/highfieldbio.com\/zh\/wp-json\/wp\/v2\/posts\/7913","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/highfieldbio.com\/zh\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/highfieldbio.com\/zh\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/highfieldbio.com\/zh\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/highfieldbio.com\/zh\/wp-json\/wp\/v2\/comments?post=7913"}],"version-history":[{"count":21,"href":"https:\/\/highfieldbio.com\/zh\/wp-json\/wp\/v2\/posts\/7913\/revisions"}],"predecessor-version":[{"id":7937,"href":"https:\/\/highfieldbio.com\/zh\/wp-json\/wp\/v2\/posts\/7913\/revisions\/7937"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/highfieldbio.com\/zh\/wp-json\/wp\/v2\/media\/7606"}],"wp:attachment":[{"href":"https:\/\/highfieldbio.com\/zh\/wp-json\/wp\/v2\/media?parent=7913"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/highfieldbio.com\/zh\/wp-json\/wp\/v2\/categories?post=7913"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/highfieldbio.com\/zh\/wp-json\/wp\/v2\/tags?post=7913"}],"curies":[{"name":"\u53ef\u6e7f\u6027\u7c89\u5242","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}